Virginia Retirement Systems ET AL decreased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 17.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,500 shares of the company’s stock after selling 13,100 shares during the period. Virginia Retirement Systems ET AL’s holdings in Zoetis were worth $3,961,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. raised its stake in Zoetis by 2,471.1% in the first quarter. BlackRock Inc. now owns 36,082,470 shares of the company’s stock valued at $1,925,722,000 after buying an additional 34,679,064 shares in the last quarter. Vanguard Group Inc. raised its stake in Zoetis by 1.7% in the first quarter. Vanguard Group Inc. now owns 32,744,421 shares of the company’s stock valued at $1,747,570,000 after buying an additional 546,287 shares in the last quarter. State Street Corp raised its stake in Zoetis by 4.9% in the first quarter. State Street Corp now owns 21,256,557 shares of the company’s stock valued at $1,134,453,000 after buying an additional 986,680 shares in the last quarter. Morgan Stanley raised its stake in Zoetis by 182.5% in the first quarter. Morgan Stanley now owns 14,617,205 shares of the company’s stock valued at $780,119,000 after buying an additional 9,442,207 shares in the last quarter. Finally, Clearbridge Investments LLC raised its stake in Zoetis by 4.2% in the first quarter. Clearbridge Investments LLC now owns 9,254,662 shares of the company’s stock valued at $493,921,000 after buying an additional 373,568 shares in the last quarter. Institutional investors own 92.70% of the company’s stock.

Zoetis Inc. (ZTS) opened at 61.33 on Friday. The company has a market capitalization of $30.00 billion, a P/E ratio of 34.67 and a beta of 1.02. The stock’s 50 day moving average price is $61.83 and its 200-day moving average price is $58.45. Zoetis Inc. has a one year low of $46.86 and a one year high of $63.85.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.53. The company had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.27 billion. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.49 earnings per share. Equities analysts forecast that Zoetis Inc. will post $2.34 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.thecerbatgem.com/2017/08/27/virginia-retirement-systems-et-al-lowers-position-in-zoetis-inc-zts.html.

Several equities research analysts recently weighed in on ZTS shares. Jefferies Group LLC lifted their price target on Zoetis from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday, May 9th. Cantor Fitzgerald set a $75.00 price target on Zoetis and gave the company a “buy” rating in a research report on Monday, August 14th. Argus restated a “buy” rating and set a $69.00 price target (up from $60.00) on shares of Zoetis in a research report on Tuesday, May 30th. CL King started coverage on Zoetis in a research report on Friday, May 26th. They set a “buy” rating and a $71.00 price target on the stock. Finally, Deutsche Bank AG restated a “buy” rating and set a $65.00 price target (up from $62.00) on shares of Zoetis in a research report on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $65.44.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.